dld 1 Search Results


dld 1  (ATCC)
99
ATCC dld 1
Dld 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld 1/product/ATCC
Average 99 stars, based on 1 article reviews
dld 1 - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
human colon cancer cell lines  (ATCC)
96
ATCC human colon cancer cell lines
Human Colon Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colon cancer cell lines/product/ATCC
Average 96 stars, based on 1 article reviews
human colon cancer cell lines - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
dld1  (DSMZ)
94
DSMZ dld1
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld1, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld1/product/DSMZ
Average 94 stars, based on 1 article reviews
dld1 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
dld1-chk1 s317a  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare dld1-chk1 s317a
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld1 Chk1 S317a, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld1-chk1 s317a/product/Johns Hopkins HealthCare
Average 90 stars, based on 1 article reviews
dld1-chk1 s317a - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human colorectal adenocarcinoma dld-1 cells  (China Center for Type Culture Collection)
90
China Center for Type Culture Collection human colorectal adenocarcinoma dld-1 cells
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Human Colorectal Adenocarcinoma Dld 1 Cells, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colorectal adenocarcinoma dld-1 cells/product/China Center for Type Culture Collection
Average 90 stars, based on 1 article reviews
human colorectal adenocarcinoma dld-1 cells - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human colon carcinoma caco-2 cells  (BioResource International Inc)
90
BioResource International Inc human colon carcinoma caco-2 cells
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Human Colon Carcinoma Caco 2 Cells, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colon carcinoma caco-2 cells/product/BioResource International Inc
Average 90 stars, based on 1 article reviews
human colon carcinoma caco-2 cells - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human colon adenocarcinoma cell lines colo 320/mdr-lrp  (LGC Promochem)
90
LGC Promochem human colon adenocarcinoma cell lines colo 320/mdr-lrp
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Human Colon Adenocarcinoma Cell Lines Colo 320/Mdr Lrp, supplied by LGC Promochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colon adenocarcinoma cell lines colo 320/mdr-lrp/product/LGC Promochem
Average 90 stars, based on 1 article reviews
human colon adenocarcinoma cell lines colo 320/mdr-lrp - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
dld-1 cells  (clea japan inc)
90
clea japan inc dld-1 cells
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld 1 Cells, supplied by clea japan inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld-1 cells/product/clea japan inc
Average 90 stars, based on 1 article reviews
dld-1 cells - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human crc cell line dld-1  (JCRB Cell Bank)
90
JCRB Cell Bank human crc cell line dld-1
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Human Crc Cell Line Dld 1, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human crc cell line dld-1/product/JCRB Cell Bank
Average 90 stars, based on 1 article reviews
human crc cell line dld-1 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
dld1 xenografts  (SG Controls Ltd)
90
SG Controls Ltd dld1 xenografts
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Dld1 Xenografts, supplied by SG Controls Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dld1 xenografts/product/SG Controls Ltd
Average 90 stars, based on 1 article reviews
dld1 xenografts - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
colorectal cancer cells  (Kitayama Labes Co Ltd)
90
Kitayama Labes Co Ltd colorectal cancer cells
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Colorectal Cancer Cells, supplied by Kitayama Labes Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/colorectal cancer cells/product/Kitayama Labes Co Ltd
Average 90 stars, based on 1 article reviews
colorectal cancer cells - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
nad-competitive parp-1 inhibitors olaparib zd-2281 lynparza  (AstraZeneca ltd)
90
AstraZeneca ltd nad-competitive parp-1 inhibitors olaparib zd-2281 lynparza
( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and <t>DLD1</t> (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.
Nad Competitive Parp 1 Inhibitors Olaparib Zd 2281 Lynparza, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nad-competitive parp-1 inhibitors olaparib zd-2281 lynparza/product/AstraZeneca ltd
Average 90 stars, based on 1 article reviews
nad-competitive parp-1 inhibitors olaparib zd-2281 lynparza - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and DLD1 (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.

Journal: Science Advances

Article Title: Microrobotic copper-rich electrochemical interfacing for targeted cancer theranostics in the gut

doi: 10.1126/sciadv.aeb5934

Figure Lengend Snippet: ( A ) Anticancer potency of Cu-CICs, formed by different duration and Φ, for HT-29 monolayer cells ( n = 18). ( B ) In vitro immunofluorescence imaging of key biomarker proteins (DLAT, FDX1, LIAS, and SDHB) involved in the cuproptosis process. ( C ) Viability of various GI cancer cell lines, including HT-29, NCI-N87 (human gastric cancer), HuTu80 (human duodenal cancer), PANC-1 (human pancreatic cancer), HCT116, LS174, and DLD1 (human colorectal cancers), after treatments with M-cuproptosis ( n ≥ 4). ( D ) Optical images and the corresponding live/dead assay results (top right) of HT-29 tumor spheroids with different sizes (0.3 mm for top and 1.3 mm for bottom) after treatment with 0, 1, 6, and 12 hour of M-cuproptosis. ( E ) In vitro adenosine triphosphate (ATP) assay results for HT-29 tumor spheroids (0.3, 1.3, and 2.5 mm) with increasing treatment duration ( n = 6 to 16). ( F ) Comparison of antitumor efficacy of 6-h M-cuproptosis fueled by Cu wires (diameter = 150 μm, P4-4 configuration) and the microrobot for 1.3-mm tumor spheroids ( n = 5 to 10). All data are means ± SD. All statistical analyses were performed using one-way analysis of variance (ANOVA). **** P < 0.0001. Scale bars, 50 μm (B) and 500 μm (D). A.U., arbitrary unit.

Article Snippet: Human GI cancer cell lines—including a colorectal adenocarcinoma cell lines HT-29 [American Type Culture Collection (ATCC)], LS174 (DSMZ), and DLD1 (DSMZ); a colorectal carcinoma cell line HCT116 (LGC Standards); a duodenal adenocarcinoma cell line HuTu 80 (ATCC); a pancreatic carcinoma cell line PANC-1 (DSMZ); a gastric adenocarcinoma cell line NCI-N87 (ATCC); an intestinal carcinoma cell line (Caco-2); and a colon epithelial cell line NCM460 (INCELL)—were purchased from each supplier and cultured according to adequate protocols.

Techniques: In Vitro, Immunofluorescence, Imaging, Biomarker Discovery, Live Dead Assay, ATP Assay, Comparison